Miriam J. Paramore - 02 Dec 2021 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Reporting relationship: PRESIDENT AND CSO
Issuer ticker: OPRX
Reported as of: 02 Dec 2021
Net transaction value: -$218,746
SEC form: 4
Accepted by SEC: 03 Dec 2021, 15:45:37 UTC
Prior SEC filing: 03 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Miriam Paramore

Key filing fact

Miriam J. Paramore filed Form 4 for OptimizeRx Corp (OPRX) on 03 Dec 2021.

Key facts

This page summarizes Miriam J. Paramore's Form 4 filing for OptimizeRx Corp (OPRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2021, 15:45.

Change

Previous filing in this sequence was filed on 03 Nov 2021.
Current net transaction value: -$218,746.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OPRX transaction

Common Stock Pursuant to 10B5-1 Plan

Sale

Transaction value: $218,746
Shares: -3,558
Change %: -4.8%
Price: $61.48
Shares after: 71,049
Date: 02 Dec 2021
Ownership: Direct
Footnotes: F1

OPRX transaction

Common Stock

Options Exercise

Transaction value: $26,721
Shares: +3,558
Change %: +5%
Price: $7.51
Shares after: 74,607
Date: 02 Dec 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OPRX transaction Derivative

Stock Option

Options Exercise

Transaction value: $26,721
Shares: -3,558
Change %: -3.8%
Price: $7.51
Shares after: 90,760
Date: 02 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,558
Exercise price: $7.51

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares sold pursuant to a plan of disposition adopted on March 24, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.